Please login to the form below

Not currently logged in
Email:
Password:

Haemostatix receives Wellcome Trust Award

Biopharma Haemostatix is to receive a £409,000 Translation Award from the Wellcome Trust to support development of its haemostat technology

Biopharmaceutical company, Haemostatix, is to receive a £409,000 Translation Award from the Wellcome Trust to support development of its innovative haemostat technology, used by surgeons to manage problematic bleeding and to reduce time in the operating theatre during surgery. The products are applied in the form of sprays, gels or pads, and typically contain the enzyme thrombin, which promotes blood clotting, as the active ingredient.

Haemostatix has developed a new class of active ingredient based on a peptide that binds to another blood clotting protein, fibrinogen, instantly forming a clot.

Dr Ben Nichols, CEO of Haemostatix, commented: "There is a real need for rapid acting, ready-to-use haemostats that are safe and cost-effective, and we believe our technology can deliver these benefits to surgeons and their patients. We have received a lot of interest from pharmaceutical companies, and this Award and the investment, will enable us to generate more data to support the commercialisation process."

Dr Richard Seabrook, head of business development at the Wellcome Trust, said: "Bleeding is a major cause of mortality during trauma and control of bleeding during surgery is essential to the outcome of procedures. If successful, a new haemostat that bypasses the need for thrombin has the potential to make a huge impact on healthcare and the Wellcome Trust is pleased to support this project."

The funding coincides with an additional £459,000 investment from Spark Ventures, Catapult Venture Managers, NESTA, the Lachesis Fund and Leicester University, as well as new investor, Mobius Life Sciences Fund.

Haemostatix is based at BioCity Nottingham, Europe's largest bioscience business incubator and was originally a spin-out from Leicester University. Dr Glenn Crocker, CEO of BioCity added: "We have provided Haemostatix with a supportive business development environment for several years and recognise the enormous progress the company has made with its new product. Mobius Life Sciences Fund is designed to contribute to this kind of investment opportunity alongside major investors and we look forward to Haemostatix' further success."

8th November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics